Comparative Effectiveness of Nintedanib and Pirfenidone in Patients Diagnosed With Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Shankar, D. [1 ]
Law, A. [1 ]
Walkey, A. J. [1 ]
Hawkins, F. J. [1 ]
Alysandratos, K. [2 ]
Wilson, K. C. [1 ]
Bosch, N. A. [1 ]
机构：
[1] Boston Univ, Sch Med, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Pulm, Boston, MA 02118 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2481
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Belhassen, Manon
    Dalon, Faustine
    Nolin, Maeva
    Van Ganse, Eric
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [2] Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Manon Belhassen
    Faustine Dalon
    Maëva Nolin
    Eric Van Ganse
    Respiratory Research, 22
  • [3] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [4] Outcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
    Cottin, V.
    Spagnolo, P.
    Bonniaud, P.
    Nolin, M.
    Dalon, F.
    Kirchgassler, K.
    Chia, J.
    Kamath, T. V.
    Van Ganse, E.
    Belhassen, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] SAFETY OF COMBINED PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Flaherty, K. R.
    Fell, C. D.
    Huggins, J. T.
    Nunes, H.
    Sussman, R.
    Valenzuela, C.
    Petzinger, U.
    Stauffer, J. L.
    Gilberg, F.
    Bengus, M.
    Wijsenbeek, M.
    THORAX, 2017, 72 : A253 - A254
  • [6] Outcomes in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
    Cottin, Vincent
    Spagnolo, Paolo
    Bonniaud, Philippe
    Nolin, Maeva
    Dalon, Faustine
    Chia, Jenny
    Kirchgassler, Klaus
    Kamath, Tripthi
    Van Ganse, Eric
    Belhassen, Manon
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 121 - 121
  • [7] COST EFFECTIVENESS OF NINTEDANIB VERSUS PIRFENIDONE TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS IN TURKEY
    Demir, O.
    Tetik, E.
    Kamaci, E.
    Cheynel, J.
    VALUE IN HEALTH, 2017, 20 (09) : A646 - A646
  • [8] A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review
    Man, Ruzhual K.
    Gogikar, Amaresh
    Nanda, Ankita
    Janga, Lakshmi Sai Niharika
    Sambe, Hembashima G.
    Yasir, Mohamed
    Ramphall, Shivana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [9] Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis
    Rajchgot, Jason
    Stanbrook, Matthew B.
    Anand, Anju
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (08) : 1105 - 1105
  • [10] Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
    Dempsey, Timothy M.
    Payne, Stephanie
    Sangaralingham, Lindsey
    Yao, Xiaoxi
    Shah, Nilay D.
    Limper, Andrew H.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (07) : 1121 - 1128
12345